Acute Safety and Efficacy of Intranasal Esketamine Spray Plus an Oral Antidepressant in Patient With Treatment-Resistant Depression From a University Hospital in Korea
Aims: There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray in Korea. This study is aimed to evaluate the acute safety and efficacy of intranasal esketamine in patients with TRD from a university hospital in Korea.
Saved in:
| Main Authors: | Sang-Yeol Lee, Kyung-Joon Min, Chan-Mo Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-06-01
|
| Series: | BJPsych Open |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472425107989/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
by: Fernando Mora, et al.
Published: (2025-08-01) -
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
by: Maxwell Z. Price, et al.
Published: (2024-12-01) -
Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression—A Pilot Study
by: Daniel Szawarnoga, et al.
Published: (2025-07-01) -
Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression
by: Alexandre Fraichot, et al.
Published: (2025-08-01) -
Optimal doses of intranasal esketamine plus dexmedetomidine for sedating toddlers during transthoracic echocardiography: a prospective, double-blind, randomized trial
by: Dongjie Pei, et al.
Published: (2025-12-01)